Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket Trial.
Clin Lung Cancer
December 2024
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Medicine, Chicago, IL.
Background: Activating mutations in the epidermal growth factor receptor (EGFR) gene occur in 7% to 23% of patients with non-small-cell lung cancer (NSCLC). A small proportion of these (3-5%) are exon 18 mutations. Neratinib, an irreversible pan-HER tyrosine kinase inhibitor (TKI), had activity in the phase II SUMMIT basket study.
View Article and Find Full Text PDFConcomitant Usage of H1-Antihistamines and Immune Checkpoint Inhibitors on Cancer Patient Survival.
Cancer Med
January 2025
Medical Data Analytics Centre, The Chinese University of Hong Kong, Hong Kong SAR, China.
Purpose: Recent research (Li et al. 2021) suggests an upregulated expression and activation of H1 receptors on macrophages in the tumor microenvironment, and concomitant H1-antihistamine use is associated with improved overall survival in patients with lung and skin cancers receiving immunotherapy. Therefore, we retrospectively evaluated the impacts of H1-antihistamine use in cancer patients during immunotherapy.
View Article and Find Full Text PDFVariables influencing telemedicine utilization via telephone appointments among rural patients.
BMC Health Serv Res
January 2025
Valley Vein Health Center, 840 Delbon Ave, Turlock, CA, 95382, USA.
Objective: To evaluate patient preferences when utilizing telemedicine.
Methods: A 5-point Likert scale questionnaire was completed by 153 patients at a rural clinic via a convenience sampling method. The survey contained 21 statements encompassing provider confidence, patient-physician rapport, and accessibility variables.
Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib.
Genome Med
December 2024
Translational Medicine, Oncology R&D, AstraZeneca, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge, CB2 0AA, UK.
Background: The introduction of poly(ADP-ribose) polymerase (PARP) inhibitors represented a paradigm shift in the treatment of ovarian cancer. Genomic data from patients with high-grade ovarian cancer in six phase II/III trials involving the PARP inhibitor olaparib were analyzed to better understand patterns and potential causes of genomic instability.
Patients And Methods: Homologous recombination deficiency (HRD) was assessed in 2147 tumor samples from SOLO1, PAOLA-1, Study 19, SOLO2, OPINION, and LIGHT using next-generation sequencing technology.
Treatment intensification with radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer.
Front Med (Lausanne)
October 2024
Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Several life-prolonging therapies with diverse mechanisms of action (MoA) are available for the treatment of metastatic hormone-sensitive/castration-resistant prostate cancer, with many patients requiring multiple lines of therapy. Nevertheless, treatment optimization to further delay disease progression and improve overall survival remains an unmet need. Despite the number of agents with differing MoAs approved for advanced prostate cancer, many patients receive only one or two life-prolonging therapies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!